Ogikubo Hospital

Running trials

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

  NCT06831734· Novo Nordisk A/S· Source

• Enrolling by invitation

  Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

  NCT06285071· Novo Nordisk A/S· Source

• Active, not recruiting

  A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

  NCT05685238· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

  NCT04082429· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

  NCT04083781· Phase 3· Novo Nordisk A/S· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Haemophilia3 recruiting

Closed trials

• Completed

  A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors

  NCT05306418· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

  NCT05053139· Phase 3· Novo Nordisk A/S· Source

• Completed

  Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

  NCT04334057· Novo Nordisk A/S· Source

• Completed

  Post-marketing Surveillance (Use Result Surveillance) With Refixia®

  NCT03875547· Novo Nordisk A/S· Source

• Completed

  A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

  NCT03587116· Phase 3· Pfizer· Source

• Completed

  Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.

  NCT01467427· Phase 3· Novo Nordisk A/S· Source